Literature DB >> 26269179

Replication-Competent Controlled Herpes Simplex Virus.

David C Bloom1, Joyce Feller1, Peterjon McAnany1, Nuria Vilaboa2, Richard Voellmy3.   

Abstract

UNLABELLED: We present the development and characterization of a replication-competent controlled herpes simplex virus 1 (HSV-1). Replication-essential ICP4 and ICP8 genes of HSV-1 wild-type strain 17syn+ were brought under the control of a dually responsive gene switch. The gene switch comprises (i) a transactivator that is activated by a narrow class of antiprogestins, including mifepristone and ulipristal, and whose expression is mediated by a promoter cassette that comprises an HSP70B promoter and a transactivator-responsive promoter and (ii) transactivator-responsive promoters that drive the ICP4 and ICP8 genes. Single-step growth experiments in different cell lines demonstrated that replication of the recombinant virus, HSV-GS3, is strictly dependent on an activating treatment consisting of administration of a supraphysiological heat dose in the presence of an antiprogestin. The replication-competent controlled virus replicates with an efficiency approaching that of the wild-type virus from which it was derived. Essentially no replication occurs in the absence of activating treatment or if HSV-GS3-infected cells are exposed only to heat or antiprogestin. These findings were corroborated by measurements of amounts of viral DNA and transcripts of the regulated ICP4 gene and the glycoprotein C (gC) late gene, which was not regulated. Similar findings were made in experiments with a mouse footpad infection model. IMPORTANCE: The alphaherpesviruses have long been considered vectors for recombinant vaccines and oncolytic therapies. The traditional approach uses vector backbones containing attenuating mutations that restrict replication to ensure safety. The shortcoming of this approach is that the attenuating mutations tend to limit both the immune presentation and oncolytic properties of these vectors. HSV-GS3 represents a novel type of vector that, when activated, replicates with the efficiency of a nonattenuated virus and whose safety is derived from deliberate, stringent regulation of multiple replication-essential genes. By directing activating heat to the region of virus administration, replication is strictly confined to infected cells within this region. The requirement for antiprogestin provides an additional level of safety, ensuring that virus replication cannot be triggered inadvertently. Replication-competent controlled vectors such as HSV-GS3 may have the potential to be superior to conventional attenuated HSV vaccine and oncolytic vectors without sacrificing safety.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26269179      PMCID: PMC4580158          DOI: 10.1128/JVI.01667-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.

Authors:  Barbara J Attardi; Janet Burgenson; Sheri A Hild; Jerry R Reel
Journal:  J Steroid Biochem Mol Biol       Date:  2004-03       Impact factor: 4.292

2.  Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity.

Authors:  M J Gough; A A Melcher; M R Crittenden; L Sanchez-Perez; R Voellmy; R G Vile
Journal:  Gene Ther       Date:  2004-07       Impact factor: 5.250

3.  Novel gene switches for targeted and timed expression of proteins of interest.

Authors:  Nuria Vilaboa; Mary Fenna; John Munson; Stephen M Roberts; Richard Voellmy
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

4.  The herpes simplex virus type 1 latency-associated transcript (LAT) enhancer/rcr is hyperacetylated during latency independently of LAT transcription.

Authors:  Nicole J Kubat; Antonio L Amelio; Nicole V Giordani; David C Bloom
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  Differential heat shock protein induction by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver.

Authors:  W F Salminen; R Voellmy; S M Roberts
Journal:  J Pharmacol Exp Ther       Date:  1997-09       Impact factor: 4.030

Review 6.  Heat shock proteins and the inflammatory response.

Authors:  P L Moseley
Journal:  Ann N Y Acad Sci       Date:  1998-09-29       Impact factor: 5.691

7.  Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination.

Authors:  J L Bramson; M Hitt; J Gauldie; F L Graham
Journal:  Gene Ther       Date:  1997-10       Impact factor: 5.250

8.  Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

Authors:  A Chahlavi; S Rabkin; T Todo; P Sundaresan; R Martuza
Journal:  Gene Ther       Date:  1999-10       Impact factor: 5.250

9.  Highly flexible ligand binding pocket of ecdysone receptor: a single amino acid change leads to discrimination between two groups of nonsteroidal ecdysone agonists.

Authors:  Mohan B Kumar; David W Potter; Robert E Hormann; Angela Edwards; Colin M Tice; Howard C Smith; Martha A Dipietro; Mitch Polley; Michael Lawless; Philippa R N Wolohan; Damodhar R Kethidi; Subba R Palli
Journal:  J Biol Chem       Date:  2004-04-23       Impact factor: 5.157

10.  Activation of heat-shock transcription factor in rat heart after heat shock and exercise.

Authors:  M Locke; E G Noble; R M Tanguay; M R Feild; S E Ianuzzo; C D Ianuzzo
Journal:  Am J Physiol       Date:  1995-06
View more
  4 in total

1.  Targeted heat activation of HSP promoters in the skin of mammalian animals and humans.

Authors:  Richard Voellmy; Olivier Zürcher; Manon Zürcher; Pierre A de Viragh; Alexis K Hall; Stephen M Roberts
Journal:  Cell Stress Chaperones       Date:  2018-02-07       Impact factor: 3.667

2.  Immunization by Replication-Competent Controlled Herpesvirus Vectors.

Authors:  David C Bloom; Robert K Tran; Joyce Feller; Richard Voellmy
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

3.  Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis.

Authors:  Emanuele Sasso; Guendalina Froechlich; Gabriella Cotugno; Anna Morena D'Alise; Chiara Gentile; Veronica Bignone; Maria De Lucia; Biljana Petrovic; Gabriella Campadelli-Fiume; Elisa Scarselli; Alfredo Nicosia; Nicola Zambrano
Journal:  Sci Rep       Date:  2020-03-09       Impact factor: 4.379

Review 4.  A Narrative Review of Cell-Based Approaches for Cranial Bone Regeneration.

Authors:  Maria I Falguera Uceda; Silvia Sánchez-Casanova; Clara Escudero-Duch; Nuria Vilaboa
Journal:  Pharmaceutics       Date:  2022-01-05       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.